HRS 5580
Alternative Names: HRS-5580; Rolapitant PRODRUG - Fujian Shengdi PharmaceuticalLatest Information Update: 24 Jul 2024
At a glance
- Originator Fujian Shengdi Pharmaceutical
- Class Antiemetics
- Mechanism of Action Neurokinin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Postoperative nausea and vomiting
Most Recent Events
- 24 Jul 2024 For MOA in intro: https://www.ncbi.nlm.nih.gov/books/NBK470394/#:~:text=NK%2D1%20receptor%20antagonists%20exhibit,peripheral%20effects%20of%20substance%20P.
- 26 Jun 2024 Fujian Shengdi Pharmaceutical plans a phase II trial for Postoperative nausea and vomiting for in China (Injection) (NCT06475846) (HRS5580-201) (CTR20242176)